AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca plc US ((AZNCF)), AstraZeneca ((DE:ZEGA)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The NIAGARA-2 study, officially titled ‘A Phase IIIb, Open-label, Single-arm, Global Study of Perioperative Durvalumab With Neoadjuvant ddMVAC or Gem/Cis in Patients With Muscle-invasive Bladder Cancer,’ aims to investigate the use of durvalumab in combination with cisplatin-based chemotherapy in a clinical setting. This study seeks to build on previous findings from the Phase III NIAGARA study, focusing on the treatment of muscle-invasive bladder cancer.
The study tests two experimental interventions: durvalumab combined with either ddMVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) or gemcitabine/cisplatin. Durvalumab, an anti-PD-L1 antibody, is intended to enhance the immune response against cancer cells.
This interventional study follows a single-group assignment model without masking, primarily aiming to treat muscle-invasive bladder cancer. The open-label design allows all participants and researchers to know the treatment being administered.
The study began on May 15, 2025, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on June 24, 2025, indicating ongoing recruitment and progress.
For AstraZeneca, the successful advancement of this study could positively influence stock performance and investor confidence, as it demonstrates continued innovation in oncology. However, competition in the oncology sector remains fierce, with other pharmaceutical giants also advancing their cancer treatment pipelines.
The NIAGARA-2 study is currently ongoing, with further details available on the ClinicalTrials portal.